Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "DiaSorin S.p.A. (DIA) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering.
DiaSorin's immunodiagnostic and molecular diagnostics offerings are integral for the diagnosis of conditions ranging from infectious and gastrointestinal diseases to bone, mineral, and endocrine disorders, including oncology, hypertension, autoimmune, neurological, and cardiac diseases. The company effectively markets its products through direct sales and an extensive network of distributors globally.
This comprehensive report offers actionable insights into DiaSorin's expansive portfolio, providing essential information on the company, its major products, and esteemed brands. Enhance your strategic decision-making capabilities with in-depth analysis of DiaSorin's development pipeline.
Report Scope:
- Gain insights with a detailed company profile covering business descriptions, key facts, major products and services, key competitors, key personnel, subsidiaries, and recent developments.
- Access a thorough analysis of all pipeline products under development, categorized by equipment type, indication, development stage, and trial status.
- Discover detailed information on each pipeline product, including territory, developmental stage, device class, regulatory pathway, application, and projected launch dates.
- Explore ongoing clinical trials with details on trial names, objectives, sponsors, design, status, phases, and estimated timelines.
Reasons to Buy:
- Strategically develop business initiatives by understanding market trends and technological advancements in the medical device pipeline.
- Refine product development, marketing, and sales strategies by analyzing competitors' portfolios.
- Craft cutting-edge Research & Development strategies for enhanced innovation.
- Implement successful market-entry and expansion strategies with key insights into competitive landscapes.
- Identify and explore advantageous in-licensing and out-licensing opportunities.
- Plan mergers and acquisitions efficiently by recognizing pivotal industry players.
- Spot emerging players with strong potential product portfolios and create strategies to maintain competitive advantage.
- Formulate competition strategies by assessing competitors' pipeline stages and clinical trials.
- Anticipate and leverage high-value additions to competitors' portfolios for optimized business growth.
Key Topics Covered
- DiaSorin SpA Company Overview
- Company Snapshot
- Pipeline Products and Ongoing Clinical Trials Overview
- Business Description
- Key Facts
- Major Products and Services
- DiaSorin SpA - Pipeline Analysis Overview
- Pipeline Products by Development Stage
- Ongoing Clinical Trials by Trial Status
- Pipeline Products Overview
- DiaSorin SpA - Key Competitors
- DiaSorin SpA - Key Employees
- Key Employee Biographies
- DiaSorin SpA - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Jun 22, 2025: DiaSorin Receives 510(K) Clearance For LIAISON MUREX Control HIV Ab/Ag HT Set
- Jun 19, 2025: Luminex Receives 510(K) Clearance For LIAISON PLEX - Gram-Positive Blood Culture Assay
- May 01, 2025: Luminex Receives FDA 510(k) Clearance for LIAISON PLEX Gram-Negative Blood Culture Assay
- Apr 18, 2025: Diasorin Receives 510(K) Clearance for Its Second Multiplex Molecular Panel for Diagnosing Bloodstream Infections on Liaison Plex
- Mar 18, 2025: Diasorin Launches the Simplexa C. Auris Direct Assay on the Liaison MDX Instrument in All Countries Accepting the CE Mark
- Jul 16, 2024: Diasorin Receives FDA De-novo Grant for the Simplexa C. Auris Direct Assay On the Liaison MDX Instrument
- Jun 24, 2024: Luminex Receives 510(K) Clearance For LIAISON PLEX Yeast Blood Culture Assay
- Apr 13, 2024: DiaSorin Obtains Pre-Market Approval (PMA) Clearance for LIAISON Biotrin Control Parvovirus B19 IgG Plus
- Mar 22, 2024: Luminex Received FDA 510(K) Clearance For NxTAG Respiratory Pathogen Panel - Expanded Version
- Oct 03, 2023: Beyond Checkpoint Inhibitors: New Cancer Vaccine Candidate Shows Promising Preclinical Results
- Appendix
- Methodology
A selection of companies mentioned in this report includes, but is not limited to:
- bioMerieux SA
- Thermo Fisher Scientific Inc.
- Sysmex Corp.
- Roche Diagnostics International Ltd.
- Danaher Corp.
- Bio-Rad Laboratories Inc.
- Siemens Healthineers AG
- Ortho Clinical Diagnostics Holdings PLC
- Qiagen N.V.
- Becton Dickinson and Co.
For more information about this company profile visit https://www.researchandmarkets.com/r/q5l5zi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
